DHR Health Institute for Research and Development Recognized as a “Top Performing Site” Once Again

Translate to Spanish or other 102 languages!

THREE-PEAT TEAM: The DHR Health Institute for Research and Development pictured here has been recognized as a “Top Performing Site” by SWOG (formerly the Southwest Oncology Group), one of the nation’s leading cancer clinical trials networks. This is the third consecutive time the Institute has received this prestigious recognition. Courtesy image
THREE-PEAT TEAM: The DHR Health Institute for Research and Development pictured here has been recognized as a “Top Performing Site” by SWOG (formerly the Southwest Oncology Group), one of the nation’s leading cancer clinical trials networks. This is the third consecutive time the Institute has received this prestigious recognition. Courtesy image
- Advertisement -

EDINBURG, Texas – The DHR Health Institute for Research and Development is delighted to announce that it has once again been recognized as a “Top Performing Site” by SWOG (formerly the Southwest Oncology Group), one of the nation’s leading cancer clinical trials networks. This marks the third consecutive time the Institute has received this prestigious distinction.

This recognition highlights the ongoing excellence and impact of the Research Institute as it continues to advance cancer research and improve patient outcomes.

“We are deeply honored and this recognition would not be possible without the assistance of the DHR Health Oncology Institute and the leadership of Dr. Jose Cruz,” said Dr. Scott Lillibridge, executive vice president for the DHR Health Institute for Research and Development.

- Advertisement -

SWOG is a global cancer research community supported by the National Cancer Institute (NCI), and recognition as a “Top Performing Site” signifies exceptional performance in clinical trial enrollment, data quality, and patient care standards.

The DHR Health Institute for Research and Development remains committed to innovation and delivering high-quality research opportunities to all residents of the Rio Grande Valley. They are located at 5323 S. McColl Road in Edinburg. For more information about clinical trials in the areas of liver, obesity, cancer, neurology, oncology and urology, call the Institute at (956) 362-2390.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Study Reveals Link Between Parent and Child Weight Is Mostly Genetic

The link between parents’ body mass index (BMI) and their children’s BMI in childhood is driven largely by genetic inheritance, rather than by any direct biological effects of parental weight during pregnancy, a new study suggests.

DHR Health Continues to Lead the Way in Treatment of Alzheimer’s Disease for the RGV

Two years after DHR Health announced it was the first hospital south of San Antonio to successfully administer Leqembi, an FDA-approved intravenous treatment for early Alzheimer’s disease, DHR Health continues to expand access to advanced Alzheimer’s care for patients in the Rio Grande Valley being now the only facility doing amyloid PET Scans, a diagnostic test to accurately diagnose Alzheimer’s disease. DHR Health also offers Kisunla, another FDA-approved intravenous treatment for early symptomatic Alzheimer’s disease.

The Genetic Armor Defeating Colorectal Cancer

A team of scientists from the Barbara Ann Karmanos Cancer Institute, Wayne State University, and institutions across the U.S., have published a landmark paper on the role of TGFBR1*6A, a naturally occurring genetic mutation in the TGFBR1 gene found in approximately 14 percent of the general population. Image for illustration purposes

Why CKM Syndrome Requires a Coordinated Care Point Person

When the term “cardiovascular-kidney-metabolic syndrome” was created in 2023 to define how heart disease, kidney disease, obesity and diabetes are connected, one goal was to help health professionals understand the benefits of working together.
- Advertisement -